

Dear Customer,

With the Brexit deadline on the horizon, access to UK-licensed medicines is understandably at the forefront of concerns for Irish community pharmacies. I would like to take this opportunity to assure all PharmaSource customers that our team have been working tirelessly on provisions for mitigating any risks to supply post-Brexit. Maintaining continuity of supply to Irish community pharmacies has been at the forefront of developing PharmaSource's Brexit strategy.

The likelihood of a 'no trade deal' Brexit is looking higher than ever. PharmaSource have identified customs implementation, delays at borders, and stock piling of medicines leading to shortages, as some of the biggest risks to continuity of supply in this scenario. In order to mitigate against any disruption in supply to Irish pharmacies, PharmaSource have increased current stock holdings of EMPs sourced directly from the UK. This additional stock holding safeguards PharmaSource's supply to Irish community pharmacies and allows us to continue to supply customers with UK-sourced medicines in the event of delays at the border.

To further mitigate against possible delays, PharmaSource's favoured freight forwarder provides an air freight solution which utilises an automated clearing process, resulting in zero disruption to lead times. Furthermore, 100% of PharmaSource's UK suppliers are committed to supplying PharmaSource with UK medicines post Brexit.

As you are aware, from 1<sup>st</sup> of January 2021, the UK will be exiting the EU single market and will become a 'third country'. PharmaSource's status as an authorised operator along with our partnership with Uniphar-owned, UK-headquartered, Durbin International, puts us in a unique position to support community pharmacies. Leveraging Durbin's global footprint, expertise, and broad supplier base, we believe that PharmaSource and Durbin working together can provide enhanced global access to unlicensed and speciality medicines to our valued pharmacy customers and their patients.

The PharmaSource Procurement Team has been working closely with our community pharmacy customers and suppliers alike to identify and source any medicines that could potentially be impacted by Brexit. However, I would encourage any customer with concerns around post-Brexit supply of medicines to contact the PharmaSource Team on [pharmasource@uniphar.ie](mailto:pharmasource@uniphar.ie) and we will liaise with you on your query directly.

In summary, I appreciate that this remains an anxious time for us all. I can guarantee that PharmaSource, and our global network of suppliers, are making all necessary preparations to ensure continuity of supply of EMPs to the Irish market post-Brexit.

Kind Regards,

**Daragh Byrne**

Business Unit Director – PharmaSource and OstomySource

PharmaSource: 1800 440 440

Email: [pharmasource@uniphar.ie](mailto:pharmasource@uniphar.ie)